Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Marinus (MRNS) and BioNTech SE (BNTX).
Marinus (MRNS)
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Marinus, with a price target of $28.00. The company’s shares closed last Tuesday at $13.87.
According to TipRanks.com, Olson is a 1-star analyst with an average return of -1.1% and a 42.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Frequency Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $28.63 average price target, a 99.1% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
BioNTech SE (BNTX)
J.P. Morgan analyst Cory Kasimov maintained a Hold rating on BioNTech SE yesterday and set a price target of $90.00. The company’s shares closed last Tuesday at $112.76, close to its 52-week high of $115.00.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.3% and a 55.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $98.00 average price target, which is a -10.9% downside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNTX:
